Unlocking Tomorrow's Cure for Cancer
Leveraging 3D In Vitro Models for Oncology Drug Discovery
Presenter: Dr Rajendra Kumari,
Global Head of Scientific Communications
The cancer resistance landscape is evolving in parallel to the identification of new targets and therapeutics or the development of novel combination strategies. Matching a promising target to the best patient population requires an arsenal of tools, in depth expertise, and models that reflect the patient clinical situation as early as the in vitro stage of preclinical drug development.
In this webinar, the first in our "Unlocking Tomorrow's Cure for Cancer" series, Dr Rajendra Kumari reviews how 2D in vitro models have contributed to the development of new agents and discuss the need to improve translatability using patient relevant 3D systems such as primary cell cultures and organoids that more faithfully recapitulate tissue architecture and drug responses seen in the clinic.
Watch this Webinar to Learn:
- The key advantages of using 3D in vitro systems, such as 3D cell line cultures and patient-derived models including organoids
- How model features, therapeutic, and target of interest can influence your decision to adopt a 3D in vitro platform for drug development
- How organoids can improve your drug discovery workflow
- When standard 3D culture should be preferred
- How to predict in vivo responses and select follow on models
Who Should Watch:
- Decision makers from biotech and pharmaceutical companies who want to optimize their early stage drug development programs
- Drug developers who are interested in exploring optimal applications of patient-derived in vitro models such as organoids and primary cells
- Scientists interested in reviewing the key benefits and challenges from current 2D and 3D in vitro models
About The Presenter:
Dr Rajendra Kumari is the Global Head of Scientific Communications for Crown Bioscience, providing scientific guidance and communications on company products, services, and R&D.
Rajendra received her PhD from the University of Leicester in Molecular Pharmacology, following which she joined the lab of Prof. Sue Watson as a postdoctoral fellow in the Division of Pre-clinical Oncology, School of Clinical Sciences, University of Nottingham (UoN). In 2005, Rajendra took the role of Project and Business Manager of the Preclinical Oncology Services (PRECOS) contract research business unit where she built up and managed the portfolio of preclinical in vitro and in vivo projects, products, team and clients, as well as marketing and developing the commercial processes of PRECOS.
Rajendra’s expertise in cancer cell biology and model development helped to build PRECOS, develop an academic career as a lecturer in the School of Clinical Sciences, as well as co-founding the Ex Vivo Pharmacology Centre of Excellence (UoN), which recapitulates the tumor microenvironment through use of clinically-derived tissue. Rajendra was pivotal in the growth of the business unit and commercialization of research which led to the establishment of the spinout of PRECOS Ltd in 2010, acting as Chief Operations Officer, Board Director and co-founder, until merger with CrownBio in July 2013 where she then acted as GM/CSO for CrownBio UK for 4 years.
Rajendra is a member of the American Association of Cancer Research, British Association of Cancer Research, the NC3Rs Cancer Research Advisory Group, and has authored over 40 abstracts and publications.